Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Key Points President Trump's tariffs could erode healthcare companies' profits, but some may perform well regardless.Eli Lilly and Novartis have taken steps to mitigate the potential impact. Both ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Scroll through any hoops-heavy feed on X, and you’ll see it. The post Our Fans Approve Blockbuster All-Star in Indy, But All ...

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

FBCG, a large-cap growth ETF, excels in bullish markets but struggles in downturns. Learn why it's rated Hold amid current ...

Analysts are all over Eli Lilly, and most suggest a "Moderate Buy." Sixteen analysts recommend buying, while three say "hold.

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

The Global Bipolar Disorder Market report forecasts significant growth from 2025 to 2035, driven by rising prevalence, awareness, and pharmacotherapy ...

The global chronic plaque psoriasis market is experiencing steady growth, propelled by increasing autoimmune disease prevalence and advancements in b ...

Detailed price information for Harvest Eli Lilly Enhanced High Income S (LLHE-T) from The Globe and Mail including charting and trades.